Chemotherapy is ingenious in reducing tumor growth and lengthening patient survival in numerous

cancers, but often tumor recurrence is seen due to cancer cell adaptive power leading to

chemoresistance and survival. Chemoresistance of cancer cells involves multiple number of pathways

and their interactions . One of the most pivotal regulatory processes involved in chemoresistance

pathways is the ubiquitin proteasome pathway. Ubiquitin-mediated proteolytic pathway has a crucial

role in the elimination of regulatory proteins involved in cell cycle regulation, cellular signalling, DNA

repair, apoptosis, protein quality control and transcriptional regulation. Emerging clinical evidence

shows that the deregulation of ubiquitin-mediated degradation of oncogene products or tumour

suppressors is likely to be involved in the physiology of cancers. Hence, our study of the involvement of

E3 ubiquitin ligase TRIM’s (Tripartite Motif proteins) activity in chemoresistance would help discern

the molecular basis and to provide novel therapeutic opportunities.

I am currently screening for the TRIM’s involved in chemoresistance in breast cancer and the pathways

regulated by them. I am also working on the cross talk between TRIM’s and proteasome during

chemoresistance.